Bionano Genomics Inc. (NASDAQ: BNGO) on January 24, 2023, started off the session at the price of $1.89, plunging -4.17% from the previous trading day. During the day, the shares moved up to $1.94 and dropped to $1.81 before settling in for the closing price of $1.92. Within the past 52 weeks, BNGO’s price has moved between $1.16 and $4.35.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 21.50%. The company achieved an average annual earnings per share of 33.60%. With a float of $291.64 million, this company’s outstanding shares have now reached $296.92 million.
The extent of productivity of a business whose workforce counts for 299 workers is very important to gauge. In terms of profitability, gross margin is +4.47, operating margin of -428.79, and the pretax margin is -434.64.
Bionano Genomics Inc. (BNGO) Insider and Institutional Ownership
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Bionano Genomics Inc. is 1.87%, while institutional ownership is 27.30%. The most recent insider transaction that took place on Aug 15, was worth 72,402. In this transaction Director of this company sold 20,000 shares at a rate of $3.62, taking the stock ownership to the 0 shares. Before that another transaction happened on May 16, when Company’s Director bought 10,000 for $1.60, making the entire transaction worth $16,000. This insider now owns 13,894 shares in total.
Bionano Genomics Inc. (BNGO) Latest Financial update
As on 6/29/2022, Multinational firm has announced its last quarter scores, in which it reported -$0.11 earnings per share (EPS) for the period falling under the consensus outlook (set at -$0.09) by -$0.02. This company achieved a net margin of -402.84 while generating a return on equity of -38.92. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 33.60% per share during the next fiscal year.
Bionano Genomics Inc. (NASDAQ: BNGO) Trading Performance Indicators
Bionano Genomics Inc. (BNGO) is currently performing well based on its current performance indicators. A quick ratio of 5.80 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.41, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.44 in one year’s time.
Technical Analysis of Bionano Genomics Inc. (BNGO)
The latest stats from [Bionano Genomics Inc., BNGO] show that its last 5-days average volume of 7.4 million was superior to 7.07 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 70.70%. Additionally, its Average True Range was 0.14.
During the past 100 days, Bionano Genomics Inc.’s (BNGO) raw stochastic average was set at 28.88%, which indicates a significant decrease from 77.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.71% in the past 14 days, which was lower than the 91.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9448, while its 200-day Moving Average is $1.9725. Now, the first resistance to watch is $1.9167. This is followed by the second major resistance level at $1.9933. The third major resistance level sits at $2.0467. If the price goes on to break the first support level at $1.7867, it is likely to go to the next support level at $1.7333. The third support level lies at $1.6567 if the price breaches the second support level.
Bionano Genomics Inc. (NASDAQ: BNGO) Key Stats
Market capitalization of the company is 507.56 million based on 296,924K outstanding shares. Right now, sales total 17,980 K and income totals -72,440 K. The company made 7,220 K in profit during its latest quarter, and -31,810 K in sales during its previous quarter.